Literatur
- 1
Ayoub W T, Franklin C M, Torretti D.
Polymyalgia reumatica. Duration of therapy
and long-term outcome.
Am J Med.
1985;
79
309-315
- 2
Behn A R, Perera T, Myles A B.
Polymyalgia rheumatica and corticosteroids: how much for how
long?.
Ann Rheum Dis.
1983;
42
374-378
- 3
Bird H A, Esselinckx W, Dixon A S, Mowat A G, Wood P H.
An evaluation of criteria for polymyalgia
rheumatica.
Ann Rheum Dis.
1979;
38
434-439
- 4
Bird H A, Leeb B F, Montecucco C M. et al .
A comparison of the sensitivity
of diagnostic criteria for polymyalgia rheumatica.
Ann
Rheum Dis.
2005;
64
626-629
- 5
Blockmans D, de Ceuninck L, Vanderschueren S. et al .
Repetitive 18F-fluorodeoxyglucose positron
emission tomography in giant cell arteritis: a prospective study
of 35 patients.
Arthritis Rheum.
2006;
55
131-137
- 6
Cantini F, Salvarani C, Niccoli L.
Remitting seronegative symmetrical synovitis with pitting edema
(RS3PE) syndrome: a prospective follow-up and magnetic resonance
imaging study.
Ann Rheum Dis.
1999;
58
230-236
- 7
Caporali R, Cimmino M, Ferracioloi G. et al .
Prednisone plus methotrexate for polymyalgia
rheumatica. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
2004;
141
493-500
- 8
Chuang T Y, Hunder G G, Ilstrup D M, Kurland L T.
Polymyalgia
rheumatica: a 10-year epidemiologic and clinical study.
Ann
Intern Med.
1982;
97
672-680
- 9
Cimmino M A, Salvarani C, Macchioni P, Gerli R. et al .
Systemic
Vasculitis Study Group of the Italian Society for Rheumatology.
Long-term follow-up of polymyalgia rheumatica patients treated with
methotrexate and steroids.
Clin Exp Rheumatol.
2008;
26
395-400
- 10
Cutolo M, Montecucco C M, Cavagna L. et al .
Serum cytokines and steroidal
hormones in polymyalgia rheumatica and elderly-onset rheumatoid
arthritis.
Ann Rheum Dis.
2006;
65
1438-1443
- 11
Dasgupta B, Hutchings A, Matteson E L.
Polymyalgia rheumatica: the mess we are
now in and what we need to do about it.
Arthritis Rheum.
2006;
55
518-520
- 12
Dasgupta B, Salvarani C, Schirmer M. et al .
Developing classification criteria for
polymyalgia rheumatica: comparison of views from an expert panel
and wider survey.
J Rheumatol.
2008;
35
270-277
- 13
Font R L, Prabhakaran C.
Histologic parameters
helpful to recognize steroid-treated temporal arteritis. An analysis of
thirty-five cases.
Br J Ophthalmol.
2007;
91
204-209
- 14
Gabriel S, Sunku J, Salvarani C. et al .
Adverse outcomes and anti-inflammatory
therapy among patients with polymyalgia rheumatica.
Arthritis
Rheum.
1997;
40
1873-1878
- 15
Hellmich B, Gross W L.
Polymyalgia
rheumatica. Myalgisches Syndrom oder okkulte Vaskulitis?.
Internist.
2005;
46
1233-1244
- 16
Hoffman G S, Cid M C, Rendt-Zagar K E. et al .
Infliximab for maintenance
of glucocorticosteroid-induced remission of giant cell arteritis.
Ann Intern Med.
2007;
146
621-630
- 17
Krüger K.
Infliximab bei Riesenzellarteriitis und Polymyalgia rheumatica
ineffektiv.
Z Rheumatol.
2007;
66
536-537
- 18
Kyle V, Hazleman B L.
Treatment of
polymyalgia rheumatica and giant cell arteritis. I. Steroid regimes
in the first 2 months.
Ann Rheum Dis.
1989;
48
658-661
- 19
Lopez-Hoyos M, de Ruiz Alegria C, Blanco R. et al .
Clinical utility of anti-CCP antibodies
in the differential diagnosis of elderly-onset rheumatoid arthritis
and polymyalgia rheumatica.
Rheumatology.
2004;
4
655-657
- 20
Maradit-Kremers H M, Reinalda M S, Crowson C S. et al .
Relapse in a population
based cohort of patients with polymyalgia rheumatica.
J
Rheumatol.
2005;
32
65-73
- 21
Narváez J, Nolla-Solé J M, Narváez J A, Clavaguera M T, Valverde-García J, Roig-Escofet D.
Musculoskeletal manifestations in polymyalgia
rheumatica and temporal arteritis.
Ann Rheum Dis.
2001;
60
1060-1063
- 22
Narváez J, Narváez J A, Nolla J M. et al .
Giant cell arteritis
and polymyalgia rheumatica: usefulness of vascular magnetic resonance
imaging studies in the diagnosis of aortitis.
Rheumatology.
2005;
44
479-483
- 23
Olivieri I, Garcia-Porrua C, Padula A. et al .
Late onset undifferentiated spondyloarthritis
presenting with polymyalgia rheumatica features: description of
seven cases.
Rheumatol Int.
2007;
27
927-933
- 24
Salvarani C, Cantini F, Boiardi L, Hunder G G.
Polymyalgia
rheumatica and giant-cell arteritis.
N Engl J Med.
2002;
347
261-271
- 25
Salvarani C, Macchioni P L, Manzini C. et al .
Infliximab plus prednisone or placebo plus
prednisone for the initial treatment of polymyalgia rheumatica.
Ann Intern Med.
2007;
146
631-639
- 26
Smeeth L, Cook C, Hall A J.
Incidence of diagnosed polymyalgia rheumatica and temporal arteritis
in the United Kingdom, 1990 to 2001.
Ann Rheum Dis.
2006;
65
1093-1098
- 27
Smetana G W, Shmerling R H.
Does this
patient have temporal arteritis?.
JAMA.
2002;
287
92-101
- 28
Schmidt W A, Gromnica-Ihle E.
Incidence of temporal
arteritis in patients with polymyalgia rheumatica: a prospective
study using colour Doppler sonography of the temporal arteries.
Rheumatology.
2002;
41
46-52
- 29 Schmidt W A, Gromnica-Ihle E, Caspary L, Stiegler H.
Polymyalgia
rheumatica und Riesenzellarteriitis (Arteriitis temporalis). In:
Dierkesmann R, Fleig WE, Heidrich H, Heimpel H, Koch KM, Meyer J,
Müller OA, Specker C (Hrsg.) Rationelle Diagnostik
und Therapie in der Inneren Medizin: Leitlinien. Elsevier.
Urban & Fischer 2006
- 30
Weyand C M, Goronzy J J.
Giant-cell
arteritis and polymyalgia rheumatica.
Ann Intern Med.
2003;
139
505-515
Prof. Dr. med. Elisabeth Märker-Hermann
Klinik Innere Medizin IV (Rheumatologie,
klinische Immunologie und Nephrologie), HSK Dr. Horst Schmidt
Klinik GmbH
Ludwig Erhard Str. 100
D-65199 Wiesbaden
Phone: 0611/436-445
Fax: 0611/436-464
Email: Elisabeth.Maerker-Hermann@HSK-Wiesbaden.de
